OCRX News Alert Ocera Therapeutics Inc (OCRX) 5.77 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Ocera Therapeutics Inc (OCRX) 5.77 $OCRX

Nasdaq stocks posting largest percentage decreases
AP - Fri Dec 05, 12:17PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
ANY: 5.99 (+0.36), MCEP: 6.07 (-0.12), MARPS: 10.17 (-0.12), OCRX: 5.77 (+0.02), FIVE: 38.76 (-0.11)

Ocera Therapeutics Promotes Michael Byrnes to Chief Financial Officer
GlobeNewswire - Wed Dec 03, 7:10AM CST
Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical-stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced the appointment of Michael Byrnes as chief financial officer.
OCRX: 5.77 (+0.02)

Ocera Therapeutics (OCRX) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 25, 7:48AM CST
Ocera Therapeutics (OCRX) Shares March Higher, Can It Continue?
OCRX: 5.77 (+0.02)

Global Irritable Bowel Syndrome Market 2015-2019: Key Vendors are Actavis, Astellas Pharma, Nestle and Takeda Pharmaceutical
M2 - Tue Nov 25, 4:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/8z6f6s/global_irritable) has announced the addition of the "Global Irritable Bowel Syndrome Market 2015-2019" report to their offering. One major trend upcoming in this market is an increase in public awareness about irritable bowel syndrome, which is expected to increase the number of treatment-seeking patients, thereby increasing the consumption of medications. Growing public awareness increases the number of treatment-seeking patients, thereby leading to increased consumption of approved medications. According to the report, the presence of huge unmet needs in the field of irritable bowel syndrome is one of the major drivers of the market. There is a lack of a significant number of drugs approved by the FDA, and the use of generics and off-label drugs causes erosion in the market share of labeled products. This provides vendors with an opportunity to produce new drugs, which can give them an edge over others and hence, grab a major portion of the market. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Product Profiles 05. Market Research Methodology 06. Introduction 07. Market Landscape 08. Market Segmentation by Mechanism of Action 09. Market Segmentation by Dosage Form 10. Market Segmentation by Indication 11. Market Segmentation by End User Gender 12. Geographical Segmentation 13. Rate of Incidence and Prevalence 14. Buying Criteria 15. Market Growth Drivers 16. Drivers and their Impact 17. Market Challenges 18. Impact of Drivers and Challenges 19. Market Trends 20. Trends and their Impact 21. Vendor Landscape 22. Pipeline Portfolio 23. Key Vendor Analysis 24. Other Reports in this Series Companies Mentioned: - Abbott - Actavis - Alba Therapeutics - Alfa Wassermann - Alizyme - Almirall - AltheRx - Ardelyx - Astellas Pharma - AstraZeneca - Bayer - Bristol Myers Squibb - Dainippon Sumitomo Pharma - Dong-A Socio Holdings - DraisPharmaceuticals - Dynogen - GlaxoSmithKline - Hanmi - ImmusanT - Ironwood - Janssen - Lexicon - Menarini - MicroDose Therapeutx - Nestle - Norgine - Novartis - Ocera Therapeutics - Ono Pharmaceutical - ParPharmaceutical For more information visit http://www.researchandmarkets.com/research/8z..._irritable
OCRX: 5.77 (+0.02), GSK: 42.85 (+0.11), NVS: 93.91 (+0.66)

Ocera up again today
Seeking Alpha - at Seeking Alpha - Mon Nov 24, 12:29PM CST

OCRX: 5.77 (+0.02)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 24, 11:46AM CST

CIMT: 8.81 (unch), CLRB: 3.02 (-0.05), MPX: 8.00 (-0.03), FATE: 4.90 (+0.23), TTPH: 38.86 (+0.53), PHMD: 1.46 (-0.03), BIND: 5.73 (+0.06), AXPW: 1.00 (-0.04), CANF: 3.70 (+0.01), SYN: 1.46 (-0.07), RNA: 18.76 (+0.10), CLIR: 7.63 (+0.16), VSCI: 0.76 (-0.07), OCRX: 5.77 (+0.02), GALE: 1.49 (-0.02), REI: 10.95 (+0.22), OGEN: 0.90 (-0.07), PTP: 73.65 (-0.03), FPRX: 26.12 (+0.07)

Ocera Therapeutics (OCRX) Worth Watching: Stock Up 9.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 24, 8:46AM CST
Ocera Therapeutics (OCRX) was a big mover last session, with shares rising over 9% on the day.
BIIB: 340.89 (+5.13), OCRX: 5.77 (+0.02), AMAG: 43.02 (+0.90), AFFX: 9.80 (+0.05)

Ocera Therapeutics' (OCRX) CEO Linda Grais on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 13, 7:47PM CST

OCRX: 5.77 (+0.02)

Ocera Therapeutics beats by $0.16
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 3:18PM CST

OCRX: 5.77 (+0.02)

Ocera Reports Third Quarter 2014 Financial Results
GlobeNewswire - Thu Nov 13, 3:09PM CST
Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced recent business highlights and reported financial results for the quarter ended September 30, 2014.
OCRX: 5.77 (+0.02)

Ocera Therapeutics to Present at Stifel 2014 Healthcare Conference
GlobeNewswire - Mon Nov 10, 7:42AM CST
Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that company management will be presenting at the Stifel 2014 Healthcare Conference being held at the Palace Hotel in New York, NY. Ocera's presentation is scheduled for Wednesday, November 19, 2014 at 3:00 PM ET in the Homes II conference room.
OCRX: 5.77 (+0.02)

Hepatic Encephalopathy Therapeutics Pipeline Review 2014 - 4 Companies & 5 Drug Profiles
M2 - Thu Nov 06, 3:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/pccbnw/hepatic) has announced the addition of the "Hepatic Encephalopathy - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hepatic Encephalopathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatic Encephalopathy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Ocera Therapeutics, Inc. - Hyperion Therapeutics, Inc. - Alfa Wassermann S.p.A - Umecrine Cognition AB Drug Profiles - rifaximin - glycerol phenylbutyrate - ornithine phenylacetate - THDP-17 - CVXL-0060 For more information visit http://www.researchandmarkets.com/research/pccbnw/hepatic
OCRX: 5.77 (+0.02), HPTX: 21.91 (-0.08)

Ocera Therapeutics to Announce Third Quarter 2014 Financial Results
GlobeNewswire - Tue Nov 04, 3:05PM CST
Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that it will release its third quarter 2014 financial results on Thursday, November 13, 2014 at approximately 4:00 p.m. Eastern Time. In conjunction with this announcement, Ocera will host a conference call on Thursday, November 13, 2014 at 4:30 p.m. Eastern Time.
OCRX: 5.77 (+0.02)

Ocera Therapeutics to Present at 13th Annual BIO Investor Forum
GlobeNewswire - Mon Sep 29, 10:29AM CDT
Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that company management will be presenting at the 13 Annual BIO Investor Forum being held at the Palace Hotel in San Francisco, California. Ocera's presentation is scheduled for Tuesday, October 7, 2014 at 3:00 PM PT in the Presidio conference room.
OCRX: 5.77 (+0.02)

Ocera Therapeutics adds Steven P. James to board
M2 - Fri Sep 19, 6:26AM CDT
Biopharmaceutical company Ocera Therapeutics (NasdaqGM:OCRX) revealed on Thursday the election of Steven P. James to its board of directors.
OCRX: 5.77 (+0.02)

Ocera Therapeutics Announces Appointment of Steven P. James to Board
GlobeNewswire - Fri Sep 19, 1:43AM CDT
Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that Steven P. James has been appointed to the Company's Board of Directors. Mr. James will serve as the Lead Independent Director and will be the Chairman of the Compensation Committee.
OCRX: 5.77 (+0.02)

Anacor Pharmaceuticals Appoints Wendell Wierenga to Its Board of Directors
Business Wire - Fri Sep 12, 7:30AM CDT
Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) today announced that its Board of Directors has appointed Wendell Wierenga, Ph.D. to serve as a Class III director until the Company's 2016 annual meeting of shareholders. Anacor also announced that Paul Klingenstein has resigned from the Board.
CYTK: 5.87 (+0.35), SNTS: (), OCRX: 5.77 (+0.02), ANAC: 30.58 (+0.16), XNPT: 7.96 (+0.32)

Global Cirrhosis Therapeutics Pipeline Review 2014 - 7 Companies & 8 Drug Profiles
M2 - Fri Sep 12, 4:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/szkbdq/cirrhosis) has announced the addition of the "Cirrhosis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cirrhosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cirrhosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Gilead Sciences, Inc. - Novartis AG - Ocera Therapeutics, Inc. - Hyperion Therapeutics, Inc. - Intercept Pharmaceuticals, Inc. - PharmaIN Corporation - Alfact Innovation Drug Profiles - ornithine phenylacetate - glycerol phenylbutyrate - obeticholic acid - simtuzumab - Stem Cell Therapy for Gastrointestinal, CNS and Endocrine and Metabolic Disorders - erismodegib - ALF-5755 - PGC Based Natriuretic Peptides For more information visit http://www.researchandmarkets.com/research/szkbdq/cirrhosis
GILD: 91.29 (+1.84), OCRX: 5.77 (+0.02), ICPT: 151.49 (+5.85), NVS: 93.91 (+0.66), HPTX: 21.91 (-0.08)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Commodity Rout Tests a Market Already Short on Nerve

Updated Category News Views 95

Some weeks the tape merely wobbles; this one started throwing furniture. By midday Wednesday, traders were staring at sharp declines in gold, silver, crude and copper while the major equity benchmarks remained underwater for the week. That is an unpleasant combination. When growth-sensitive commodities and the usual hard-asset hiding places are all getting sold,...

Continue Reading
Five SEAL Medal of Honor Signatures, One Charity Lot

Updated Category News Views 35

A single rifle can carry a staggering amount of meaning when the names on it belong to all five living U.S. Navy SEAL Medal of Honor recipients. Rock Island Auction Company plans to offer that one-of-a-kind custom precision rifle during its December 4–6, 2026 Premier Firearms Auction, and the financial arrangement is unusually clean: 100% of proceeds are slated for the...

Continue Reading
AI Search Is Squeezing Clicks, Not Killing Content Yet

Updated Category News Views 121

A search result that answers the question before earning a click is a nasty little disruption, and marketers are plainly feeling around for solid ground. Goodfirms surveyed 192 content marketing professionals for its 2026 Content Engagement Metrics report, and the headline is more resilient than the prevailing panic: 66.3% said organic website traffic grew over the prior...

Continue Reading
Tigerlily Takes Its Advocacy Model to Ovarian Cancer

Updated Category News Views 136

Ovarian cancer has a nasty habit of hiding behind symptoms people are taught to shrug off. Persistent bloating or pelvic pain can look like any number of ordinary problems, and that ambiguity is exactly why practical, trusted education matters. Tigerlily Foundation's new ovarian cancer initiative is not a flashy breakthrough claim. It is a grounded attempt to help women...

Continue Reading
Africa’s Digital Ownership Debate Gets More Serious

Updated Category News Views 70

Ownership was the uncomfortable word hanging over Cape Town on day two of Africa Tech Festival 2026, and frankly it should make investors sit up. Africa’s digital economy has no shortage of big promises, shiny AI demos or overseas executives talking about opportunity. The harder question is who funds the pipes, owns the data, makes the rules and actually keeps the...

Continue Reading
YPF’s 2027 Reserves Platform Move Deserves Attention

Updated Category News Views 123

Reservoir software rarely makes anyone pound the table, but this one deserves a hard look. YPF, Argentina’s largest oil and gas company, says it will begin deploying Ikon Science’s MOSAIC reserves planning and management platform in 2027. That is not a new well, a pipeline expansion, or a barrel-count upgrade. It is the machinery behind the machinery: the systems used...

Continue Reading
LiberNovo's European Black Friday Sale Tests Demand

Updated Category News Views 155

A €1,339 chair has no business pretending it is an impulse buy, which is exactly why LiberNovo’s Black Friday push deserves a closer look. The Hong Kong-based ergonomic-chair seller has rolled out its Black Friday sale across the European Union and United Kingdom, with the campaign ending November 30 at 23:59 CET in the EU and 23:59 GMT in the UK. This is a...

Continue Reading
SAFE Wins Missouri Guard UH-60 Platform Contract Again

Updated Category News Views 96

Helicopter maintenance is one of those businesses where a few feet of floor space can matter more than a glossy brochure full of promises. SAFE Structure Designs has landed a new contract to supply custom wraparound maintenance platforms for UH-60 helicopters at the Missouri Army National Guard facility in Springfield, Missouri. No price was disclosed, no delivery...

Continue Reading
Arbor Realty's Loan Mess Meets a Dividend Shutdown

Updated Category News Views 111

A dividend suspension lands differently when the loan book is already coughing up smoke. Arbor Realty Trust’s latest disclosed numbers are not the sort that investors can shrug off as one ugly quarter and forget by Friday. The company reported a third-quarter 2026 GAAP net loss of $85.4 million, suspended its quarterly cash dividend effective immediately, and described...

Continue Reading
Robert Half's Parent Support Earns Fortune Recognition

Updated Category News Views 39

A workplace award rarely moves a staffing stock by itself, and it shouldn’t. Still, Fortune naming Robert Half among its Best Workplaces for Parents for 2026 is more than decorative corporate wallpaper. In the talent business, the company’s own ability to recruit, retain and support people is part of the product. Clients hire Robert Half because they need skilled...

Continue Reading

Top 5 Most Recently Viewed Articles

Helium One Global Ltd Advances Development Drilling Project

Updated Category News Views 381

Helium One Global Ltd Advances Development Drilling Project Helium One Global Ltd (LON: HE1H) (AIM: HE1), a notable helium exploration firm, has embarked on a significant journey with its development drilling at the Galactica-Pegasus project. This project, indicating Helium One's ambition to be a prominent figure in the helium sector, is located in Las Animas County,...

Continue Reading
FieldRoutes Introduces Innovative Features for Service Businesses

Updated Category News Views 77

FieldRoutes Enhances Service Management with Bundles Field service businesses are constantly seeking innovative ways to improve efficiency and customer satisfaction, and at the recent PestWorld conference, FieldRoutes stepped up to the plate. This leading cloud-based and mobile SaaS provider has unveiled its exciting new Bundles feature, aimed at elevating service...

Continue Reading
Exciting Updates on JLT Mobile Computers' Upcoming Meeting

Updated Category News Views 289

Invitation to the Annual General Meeting of JLT Mobile Computers JLT Mobile Computers AB (publ) is inviting its valued shareholders to participate in the Annual General Meeting (AGM). This significant event is set to take place on a Wednesday at 4:00 pm at PM & Vänner Hotel. Eligibility to Attend the Meeting To attend the meeting, it is essential that shareholders are...

Continue Reading
Ambius Collaborates to Transport Historic Trees for Remembrance

Updated Category News Views 214

Ambius Partners in an Environmental Tribute Ambius, a well-known provider of interior landscaping and plant services, has joined hands with the Anne Frank Center USA to undertake an inspiring project. This collaboration involves transporting sapling trees that are direct descendants of the historic horse chestnut tree that grew outside of Anne Frank's hiding spot. These...

Continue Reading
Caterpillar Foundation Celebrates $1 Billion in Charitable Impact

Updated Category News Views 259

Caterpillar Foundation Reaches $1 Billion Global Giving Milestone Since its inception, the Caterpillar Foundation has made remarkable strides in philanthropy, aiding over 11,000 charities across diverse regions. Recently, it achieved an inspiring milestone by surpassing $1 billion in global donations. This achievement underscores the Foundation's steadfast commitment to...

Continue Reading